MA44226B1 - Dérivés de 6,7-dihydro-5h-benzo[7]annulène comme modulateurs de récepteurs d' oestrogènes - Google Patents
Dérivés de 6,7-dihydro-5h-benzo[7]annulène comme modulateurs de récepteurs d' oestrogènesInfo
- Publication number
- MA44226B1 MA44226B1 MA44226A MA44226A MA44226B1 MA 44226 B1 MA44226 B1 MA 44226B1 MA 44226 A MA44226 A MA 44226A MA 44226 A MA44226 A MA 44226A MA 44226 B1 MA44226 B1 MA 44226B1
- Authority
- MA
- Morocco
- Prior art keywords
- group
- hydrogen atom
- benzo
- dihydro
- estrogen receptor
- Prior art date
Links
- DTRRHWQMEXXDFE-UHFFFAOYSA-N 8,9-dihydro-7h-benzo[7]annulene Chemical class C1CCC=CC2=CC=CC=C21 DTRRHWQMEXXDFE-UHFFFAOYSA-N 0.000 title 1
- 239000002834 estrogen receptor modulator Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 125000004431 deuterium atom Chemical group 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 229910052731 fluorine Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La présente invention concerne des composés de formule (i) : r1 et r2 représentent des atomes d'hydrogène ou de deutérium; r3 représente un atome d'hydrogène ou un groupe -cooh, -oh ou -opo(oh)2; r4 représente un atome d'hydrogène ou un atome de fluor; r5 représente un atome d'hydrogène ou un groupe -oh; au moins l'un de r3 ou r5 étant différent d'un atome d'hydrogène; quand r3 représente un groupe -cooh, -oh ou -opo(oh)2, alors r5 représente un atome d'hydrogène; quand r5 représente un groupe -oh, alors r3 et r4 représentent des atomes d'hydrogène; et r6 est choisi parmi un groupe phényle, hétéroaryle, cycloalkyle ou hétérocycloalkyle éventuellement substitué. L'invention concerne également la préparation et les utilisations thérapeutiques des composés de formule (i) en tant qu'inhibiteurs et agents de dégradation de récepteurs des œstrogènes, utilisés en particulier pour le traitement du cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16305174 | 2016-02-15 | ||
PCT/EP2017/053282 WO2017140669A1 (fr) | 2016-02-15 | 2017-02-14 | Dérivés de 6,7-dihydro-5h-benzo[7]annulène utilisés en tant que modulateurs de récepteurs des oestrogènes |
Publications (1)
Publication Number | Publication Date |
---|---|
MA44226B1 true MA44226B1 (fr) | 2021-07-29 |
Family
ID=55398242
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046479A MA46479A (fr) | 2016-02-15 | 2017-02-14 | Procédés et intermédiaires pour la préparation de nouveaux composés substitués de 6,7-dihydro-5h-benzo[7]annulène |
MA44226A MA44226B1 (fr) | 2016-02-15 | 2017-02-14 | Dérivés de 6,7-dihydro-5h-benzo[7]annulène comme modulateurs de récepteurs d' oestrogènes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046479A MA46479A (fr) | 2016-02-15 | 2017-02-14 | Procédés et intermédiaires pour la préparation de nouveaux composés substitués de 6,7-dihydro-5h-benzo[7]annulène |
Country Status (37)
Country | Link |
---|---|
US (6) | US9714221B1 (fr) |
EP (2) | EP3524600B1 (fr) |
JP (4) | JP6425852B1 (fr) |
KR (2) | KR20220098057A (fr) |
CN (2) | CN112979524A (fr) |
AR (1) | AR107616A1 (fr) |
AU (2) | AU2017221083B2 (fr) |
BR (1) | BR112018016490A2 (fr) |
CA (1) | CA3014424A1 (fr) |
CL (1) | CL2018002290A1 (fr) |
CO (1) | CO2018009534A2 (fr) |
CR (1) | CR20180442A (fr) |
CY (1) | CY1125165T1 (fr) |
DK (2) | DK3524600T3 (fr) |
DO (1) | DOP2018000184A (fr) |
EA (2) | EA038639B1 (fr) |
EC (1) | ECSP18069466A (fr) |
ES (2) | ES2906208T3 (fr) |
HR (1) | HRP20211043T1 (fr) |
HU (2) | HUE055107T2 (fr) |
IL (2) | IL261099B (fr) |
LT (1) | LT3416962T (fr) |
MA (2) | MA46479A (fr) |
MX (2) | MX2020011469A (fr) |
MY (1) | MY196486A (fr) |
PE (1) | PE20181893A1 (fr) |
PH (1) | PH12018501679A1 (fr) |
PL (1) | PL3416962T3 (fr) |
PT (1) | PT3416962T (fr) |
RS (1) | RS62132B1 (fr) |
SG (2) | SG11201806829TA (fr) |
SI (1) | SI3416962T1 (fr) |
TN (1) | TN2018000285A1 (fr) |
TW (3) | TWI737681B (fr) |
UY (1) | UY37124A (fr) |
WO (1) | WO2017140669A1 (fr) |
ZA (1) | ZA201805137B (fr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6425852B1 (ja) * | 2016-02-15 | 2018-11-21 | サノフイSanofi | エストロゲン受容体調節剤としての6,7−ジヒドロ−5h−ベンゾ[7]アヌレン誘導体 |
WO2018091153A1 (fr) * | 2016-11-17 | 2018-05-24 | Sanofi | Nouveaux composés n-(3-fluoropropyl)-pyrrolidine substitués, leurs procédés de préparation et leurs utilisations thérapeutiques |
AU2018217809A1 (en) | 2017-02-10 | 2019-08-22 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
EP3434272A1 (fr) | 2017-07-25 | 2019-01-30 | Sanofi | Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique |
US11759450B2 (en) | 2018-02-06 | 2023-09-19 | The Board Of Trustees Of The University Of Illinois | Substituted benzothiophene analogs as selective estrogen receptor degraders |
AU2019321588A1 (en) | 2018-08-17 | 2021-03-04 | Genentech, Inc. | Diagnostic and therapeutic methods for the treatment of breast cancer |
MX2021002666A (es) * | 2018-09-07 | 2021-07-16 | Sanofi Sa | Proceso para la preparacion de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-( 3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]a nulen-2-carboxilato de metilo. |
EP3699167A1 (fr) * | 2019-02-22 | 2020-08-26 | Sanofi | Procédé de préparation de méthyl 1-benzosuberone-7-carboxylate |
JP2022531898A (ja) | 2019-05-09 | 2022-07-12 | サノフイ | 転移性または進行性乳房がん患者において使用するための6-(2,4-ジクロロフェニル)-5-[4-[(3s)-1-(3-フルオロプロピル)ピロリジン-3-イル]オキシフェニル]-8,9-ジヒドロ-7h-ベンゾ[7]アヌレン-2-カルボン酸 |
KR102058384B1 (ko) * | 2019-09-06 | 2019-12-24 | 강원대학교산학협력단 | 2h-벤조[7]에눌렌 화합물 및 이의 제조방법 |
JP2022552132A (ja) | 2019-10-01 | 2022-12-15 | サノフイ | 新規の置換6,7-ジヒドロ-5h-ベンゾ[7]アンヌレン化合物、その製造方法およびその治療的使用 |
CA3160897A1 (fr) * | 2019-12-09 | 2021-06-17 | Sanofi | Forme cristalline d'un derive d'acide 7h-benzo[7]annulene-2-carboxylique |
TW202146007A (zh) * | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司(alpelisib)與6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸之組合 |
CN113896669A (zh) * | 2020-06-22 | 2022-01-07 | 江苏先声药业有限公司 | 雌激素受体调节剂及其用途 |
JP7419575B2 (ja) | 2020-06-28 | 2024-01-22 | メッドシャイン ディスカバリー インコーポレイテッド | 縮合環インダゾール系化合物 |
WO2022084280A1 (fr) | 2020-10-19 | 2022-04-28 | Sanofi | Composés 6,7-dihydro-5h-benzo[7]annulène substitués et leurs dérivés, processus permettant leur préparation et utilisations thérapeutiques associées |
KR20230095996A (ko) | 2020-10-19 | 2023-06-29 | 사노피 | 치환 6,7-디히드로-5h-벤조[7]아눌렌 화합물 및 이의 유도체, 이의 제조 방법 및 이의 치료적 용도 |
JP2023551192A (ja) | 2020-11-23 | 2023-12-07 | サノフイ | 乳がんにおける内分泌療法のモニタリングに使用するためのer制御遺伝子のパネル |
IL303041A (en) * | 2020-11-23 | 2023-07-01 | Sanofi Sa | Combinations containing abamciclib, and 6-(2,4-DICHLOROPHENYL)-5-[4-[(3S)-1-(3-FLUOROPROPYL)PYRROLIDIN-3-YL]OXYPHENYL]-8,9-DIHYDRO-7H-BENZO [7]ANNULENE-2-CARBOXYLIC ACID |
US20240132482A1 (en) * | 2021-02-04 | 2024-04-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Benzo seven-membered ring bifunctional compound and application thereof |
TW202304424A (zh) | 2021-04-12 | 2023-02-01 | 法商賽諾菲公司 | 包含依維莫司和安森司群的組合 |
TW202304425A (zh) | 2021-04-12 | 2023-02-01 | 法商賽諾菲公司 | 包含瑞博西尼和安森司群(amcenestrant)的組合 |
TW202313558A (zh) * | 2021-07-08 | 2023-04-01 | 大陸商勤浩醫藥(蘇州)有限公司 | 一類苯并七元環類化合物及其應用 |
WO2023287938A1 (fr) | 2021-07-15 | 2023-01-19 | Teva Pharmaceuticals International Gmbh | Formes à l'état solide d'amcenestrant |
WO2023125700A1 (fr) * | 2021-12-28 | 2023-07-06 | 南京明德新药研发有限公司 | Forme saline et forme cristalline d'un composé de tétrahydrocyclohepta indazole |
TW202400136A (zh) | 2022-03-13 | 2024-01-01 | 法商賽諾菲公司 | 以安森司群(amcenestrant)治療乳癌 |
WO2023187086A1 (fr) | 2022-03-31 | 2023-10-05 | Sanofi | Forme solide amorphe d'amcenestrant |
WO2023198901A1 (fr) | 2022-04-15 | 2023-10-19 | Sanofi | Nouveaux dérivés de 4-amino-4-oxo-but-2-ényle substitués, leurs procédés de préparation et leurs utilisations thérapeutiques |
WO2023198879A1 (fr) | 2022-04-15 | 2023-10-19 | Sanofi | Nouveaux composés de n-propyl-pyrrolidine fluorés substitués, leurs procédés de préparation et leurs utilisations thérapeutiques |
WO2023198904A1 (fr) | 2022-04-15 | 2023-10-19 | Sanofi | Dérivés de 6,7-dihydro-5h-benzo[7]annulène substitués, leurs procédés de préparation et leurs utilisations thérapeutiques |
WO2023198907A1 (fr) | 2022-04-15 | 2023-10-19 | Sanofi | Dérivés de 6,7-dihydro-5h-benzo[7]annulène substitués, procédés pour leur préparation et utilisations thérapeutiques associées |
WO2023198905A1 (fr) | 2022-04-15 | 2023-10-19 | Sanofi | Nouveaux composés de de vinyl-n-propyl-pyrrolidine fluorés substitués, leurs procédés de préparation et leurs utilisations thérapeutiques |
WO2023198903A1 (fr) | 2022-04-15 | 2023-10-19 | Sanofi | Nouveaux composés de n-propyl-pyrrolidine et de n-propyl-azétidine fluorés substitués, leurs procédés de préparation et leurs utilisations thérapeutiques |
WO2024006776A1 (fr) * | 2022-06-27 | 2024-01-04 | Relay Therapeutics, Inc. | Agents de dégradation des récepteurs alpha des oestrogènes et leur utilisation médicale |
WO2024042163A1 (fr) | 2022-08-25 | 2024-02-29 | Sanofi | Nouveaux dérivés d'acide 2,3,4,9-tétrahydro-1h-pyrido[3,4-b]indole carboxylique substitués, leurs procédés de préparation et leurs utilisations thérapeutiques |
WO2024042157A1 (fr) | 2022-08-25 | 2024-02-29 | Sanofi | Nouveaux dérivés d'acide carboxylique de quinoléine et de tétrahydronaphtalène substitués et leurs utilisations thérapeutiques |
WO2024042152A1 (fr) | 2022-08-25 | 2024-02-29 | Sanofi | Nouveaux dérivés d'acide 2-carbonyl-benzothiophene-6-carboxylique substitués, leurs procédés de préparation et leurs utilisations thérapeutiques |
WO2024042187A1 (fr) | 2022-08-25 | 2024-02-29 | Sanofi | Nouveaux dérivés d'acide benzothiophène-6-carboxylique substitués, leurs procédés de préparation et leurs utilisations thérapeutiques |
WO2024042185A1 (fr) | 2022-08-25 | 2024-02-29 | Sanofi | Nouveaux dérivés d'acide tétrahydroisoquinoléine-6-carboxylique substitués, leurs procédés de préparation et leurs utilisations thérapeutiques |
WO2024052518A1 (fr) | 2022-09-09 | 2024-03-14 | Sanofi | Dérivés de tétrahydrocyclohepta[e]indole substitués, leurs procédés de préparation et leurs utilisations thérapeutiques |
WO2024100236A1 (fr) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Polythérapies pour le traitement du cancer |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992015579A1 (fr) * | 1991-03-08 | 1992-09-17 | Rhone-Poulenc Rorer International (Holdings) Inc. | Composes polyaromatiques et multicycliques a base d'amines tertiaires, ayant une fonction inhibitrice de la squalenesynthetase |
DE19833786A1 (de) * | 1998-07-18 | 2000-01-20 | Schering Ag | Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
EP1229036B1 (fr) | 2001-01-24 | 2005-01-12 | CHIESI FARMACEUTICI S.p.A. | Derivés de 2H-1-benzopyran, procédés pour leur preparation et compositions pharmaceutique les contenant |
WO2003016270A2 (fr) * | 2001-08-11 | 2003-02-27 | Bristol-Myers Squibb Pharma Company | Modulateurs selectifs de recepteur d'oestrogene |
DK1501819T3 (da) | 2002-04-24 | 2011-01-10 | Merck Sharp & Dohme | Østrogenreceptormodulatorer |
JP4500689B2 (ja) * | 2002-12-26 | 2010-07-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的エストロゲン受容体モジュレーター |
AU2004268455B2 (en) * | 2003-08-29 | 2009-12-17 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding S1P receptor and pharmaceutical use thereof |
CA2571587C (fr) * | 2004-06-25 | 2013-02-12 | Janssen Pharmaceutica, N.V. | Antagonistes de ccr2 a base de sels quaternaires |
US20050288238A1 (en) * | 2004-06-28 | 2005-12-29 | Pfizer Inc | Benzocyclodecane derivatives with antitumor activity |
DE102005014090A1 (de) * | 2005-03-22 | 2006-09-28 | Schering Ag | 5H-Benzocycloheptenderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
JP5354775B2 (ja) * | 2005-06-14 | 2013-11-27 | ベイラー ユニバーシティ | チューブリン結合活性を有するコンブレタスタチンアナログ |
EP2048126A1 (fr) * | 2007-10-11 | 2009-04-15 | Bayer Schering Pharma AG | Dérivés de benzocycloheptanes en tant qu'oestrogènes actifs de manière sélective |
EP2090579A1 (fr) * | 2008-01-29 | 2009-08-19 | Sanofi-Aventis | Dérivés d'hétéroarylamide diazépinopyrimidone substitués |
DE102010030538A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
WO2012068284A2 (fr) * | 2010-11-16 | 2012-05-24 | Baylor University | Procédé efficace de préparation de benzosubérènes fonctionnalisés |
TW201329025A (zh) * | 2011-11-01 | 2013-07-16 | Astex Therapeutics Ltd | 醫藥化合物 |
DE102011087987A1 (de) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
CN102584687A (zh) | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 作为选择性雌激素受体调节剂的乙烯衍生物 |
CA2861939A1 (fr) * | 2011-12-30 | 2013-07-04 | Centaurus Biopharma Co., Ltd. | Nouveaux derives d'arylalcene et utilisation de ceux-ci en tant que modulateurs selectifs de recepteur d'oestrogene |
KR20150119926A (ko) * | 2013-02-19 | 2015-10-26 | 바이엘 파마 악티엔게젤샤프트 | 비시클로 2,3-벤조디아제핀 및 스피로시클릭 치환된 2,3-벤조디아제핀 |
WO2015028409A1 (fr) * | 2013-08-27 | 2015-03-05 | Bayer Pharma Aktiengesellschaft | Dérivés de 6,7-dihydro-5h-benzo[7]annulène, procédé pour les préparer, préparations pharmaceutiques les contenant et leur utilisation pour fabriquer des médicaments |
WO2016097072A1 (fr) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Modulateurs des récepteurs des oestrogènes tétrahydro-pyrido[3,4-b]indole et utilisations associées |
EP3233828B1 (fr) | 2014-12-18 | 2020-03-04 | F. Hoffmann-La Roche AG | Modulateurs des recepteurs des oestrogenes et leurs utilisations |
IL255148B2 (en) | 2015-04-29 | 2023-04-01 | Radius Pharmaceuticals Inc | 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation |
CN106924210A (zh) | 2015-12-29 | 2017-07-07 | 北京新领先医药科技发展有限公司 | 一种含有帕布昔利布的胶囊剂及其制备方法 |
JP6425852B1 (ja) * | 2016-02-15 | 2018-11-21 | サノフイSanofi | エストロゲン受容体調節剤としての6,7−ジヒドロ−5h−ベンゾ[7]アヌレン誘導体 |
WO2018091153A1 (fr) | 2016-11-17 | 2018-05-24 | Sanofi | Nouveaux composés n-(3-fluoropropyl)-pyrrolidine substitués, leurs procédés de préparation et leurs utilisations thérapeutiques |
-
2017
- 2017-02-14 JP JP2018515615A patent/JP6425852B1/ja active Active
- 2017-02-14 WO PCT/EP2017/053282 patent/WO2017140669A1/fr active Application Filing
- 2017-02-14 EA EA202090255A patent/EA038639B1/ru unknown
- 2017-02-14 EP EP19164243.8A patent/EP3524600B1/fr active Active
- 2017-02-14 CR CR20180442A patent/CR20180442A/es unknown
- 2017-02-14 ES ES19164243T patent/ES2906208T3/es active Active
- 2017-02-14 MX MX2020011469A patent/MX2020011469A/es unknown
- 2017-02-14 TN TNP/2018/000285A patent/TN2018000285A1/en unknown
- 2017-02-14 KR KR1020227002702A patent/KR20220098057A/ko unknown
- 2017-02-14 TW TW106104698A patent/TWI737681B/zh active
- 2017-02-14 MA MA046479A patent/MA46479A/fr unknown
- 2017-02-14 SG SG11201806829TA patent/SG11201806829TA/en unknown
- 2017-02-14 PT PT177058427T patent/PT3416962T/pt unknown
- 2017-02-14 LT LTEP17705842.7T patent/LT3416962T/lt unknown
- 2017-02-14 CO CONC2018/0009534A patent/CO2018009534A2/es unknown
- 2017-02-14 AU AU2017221083A patent/AU2017221083B2/en active Active
- 2017-02-14 HU HUE17705842A patent/HUE055107T2/hu unknown
- 2017-02-14 TW TW110118420A patent/TWI779620B/zh active
- 2017-02-14 UY UY0001037124A patent/UY37124A/es not_active Application Discontinuation
- 2017-02-14 SG SG10202106024XA patent/SG10202106024XA/en unknown
- 2017-02-14 MA MA44226A patent/MA44226B1/fr unknown
- 2017-02-14 AR ARP170100360A patent/AR107616A1/es unknown
- 2017-02-14 US US15/432,470 patent/US9714221B1/en active Active
- 2017-02-14 MX MX2018009908A patent/MX2018009908A/es unknown
- 2017-02-14 EP EP17705842.7A patent/EP3416962B1/fr active Active
- 2017-02-14 CN CN202110173352.7A patent/CN112979524A/zh active Pending
- 2017-02-14 DK DK19164243.8T patent/DK3524600T3/da active
- 2017-02-14 PE PE2018001528A patent/PE20181893A1/es unknown
- 2017-02-14 MY MYPI2018702684A patent/MY196486A/en unknown
- 2017-02-14 DK DK17705842.7T patent/DK3416962T3/da active
- 2017-02-14 HU HUE19164243A patent/HUE057892T2/hu unknown
- 2017-02-14 SI SI201730819T patent/SI3416962T1/sl unknown
- 2017-02-14 PL PL17705842T patent/PL3416962T3/pl unknown
- 2017-02-14 RS RS20210923A patent/RS62132B1/sr unknown
- 2017-02-14 CA CA3014424A patent/CA3014424A1/fr active Pending
- 2017-02-14 CN CN201780023088.0A patent/CN108884079B/zh active Active
- 2017-02-14 EA EA201891841A patent/EA034994B1/ru not_active IP Right Cessation
- 2017-02-14 ES ES17705842T patent/ES2881508T3/es active Active
- 2017-02-14 KR KR1020187026518A patent/KR20180105759A/ko not_active Application Discontinuation
- 2017-02-14 BR BR112018016490-9A patent/BR112018016490A2/pt active Search and Examination
- 2017-02-14 TW TW110118421A patent/TWI779621B/zh active
- 2017-06-05 US US15/613,689 patent/US10570090B2/en active Active
-
2018
- 2018-07-31 ZA ZA2018/05137A patent/ZA201805137B/en unknown
- 2018-08-07 PH PH12018501679A patent/PH12018501679A1/en unknown
- 2018-08-10 DO DO2018000184A patent/DOP2018000184A/es unknown
- 2018-08-10 CL CL2018002290A patent/CL2018002290A1/es unknown
- 2018-08-12 IL IL261099A patent/IL261099B/en active IP Right Grant
- 2018-09-13 EC ECSENADI201869466A patent/ECSP18069466A/es unknown
- 2018-10-22 JP JP2018198269A patent/JP6476343B2/ja active Active
-
2019
- 2019-02-01 JP JP2019016703A patent/JP6695457B2/ja active Active
-
2020
- 2020-01-15 US US16/743,504 patent/US20200392081A1/en not_active Abandoned
- 2020-04-21 JP JP2020075207A patent/JP6868142B2/ja active Active
- 2020-10-01 IL IL277750A patent/IL277750B/en unknown
- 2020-12-17 US US17/124,852 patent/US11214541B2/en active Active
-
2021
- 2021-06-30 HR HRP20211043TT patent/HRP20211043T1/hr unknown
- 2021-09-02 AU AU2021225215A patent/AU2021225215B2/en not_active Expired - Fee Related
- 2021-11-22 US US17/532,051 patent/US20220073460A1/en not_active Abandoned
-
2022
- 2022-02-16 CY CY20221100140T patent/CY1125165T1/el unknown
-
2023
- 2023-10-12 US US18/379,576 patent/US20240150284A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44226B1 (fr) | Dérivés de 6,7-dihydro-5h-benzo[7]annulène comme modulateurs de récepteurs d' oestrogènes | |
MA27573A1 (fr) | Sinomenine et derives de sinomenine, synthese et utilisation. | |
TN2014000147A1 (fr) | Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique | |
MA45020A (fr) | Dérivés sulfonamides aromatiques | |
TNSN04151A1 (fr) | Derives de nicotinamide utiles comme inhibiteurs de pde4 | |
MA30778B1 (fr) | Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques | |
MA29377B1 (fr) | Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif | |
CA2397636A1 (fr) | Derives amines de dihydro-1,3,5-triazine et leurs applications en therapeutique | |
FR3087439B1 (fr) | Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone) | |
MA33923B1 (fr) | Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a | |
MA49127B1 (fr) | Dérivés d'indole n-substitués | |
MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
MA42769B1 (fr) | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
KR970074763A (ko) | 불소화된 비타민 d₃ 유사체 | |
RU2012134454A (ru) | Агент для профилактики или уменьшения пигментации | |
MA38659B1 (fr) | Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate | |
FR2374903A1 (fr) | Nouvelle association utilisable en medecine veterinaire | |
FR3039767B1 (fr) | Composition destinee a vectoriser un agent anticancereux | |
FR3075619B1 (fr) | Derives xylosides de resveratrol pour leur utilisation en cosmetique | |
MA56508B1 (fr) | Inhibiteur de l'egfr pour le traitement du cancer | |
FR3097223B1 (fr) | Adduits silylés, polymères silylés et compositions les comprenant | |
KR940701260A (ko) | 스테로이드 함유 안구용 약제조성물, 이것을 녹내장 치료에 사용하는 방법 및 이것의 제조방법 | |
MX2023008250A (es) | Compuestos de derivados sustituidos en 4,6 de ip4. | |
MX2022014200A (es) | Derivado de 1,4,5,6-tetrahidropirimidin-2-amina. | |
FR3082120B1 (fr) | Tensioactif pour emulsion eau dans huile |